Lawrence Bressler is a seasoned pharmaceutical executive with over 20 years of experience specializing in rare disease commercialization, marketing, market access, and product launches. Most recently, he served as Vice President of Marketing at Disc Medicine, where he drove commercialization and marketing strategies for hematologic rare dissease therapies. Previously, he was part of the founding team at Chiesi Global Rare Diseases, leading Global/US Marketing and Market Access, and served as VP, Global Launch Lead at Rhythm Pharmaceuticals, crafting launch plans and innovative physician solutions like genetic testing programs. At Shire, he spearheaded pre-launch commercial planning for eosinophilic esophagitis and hereditary angioedema, building on earlier successes at GSK—where he directed a pediatric vaccine strategy generating over $1B annually—and Merck. Holding a Bachelor’s from the University of Michigan, a J.D. from Boston University, and an M.B.A. from Duke University, Bressler is a proven strategist and leader who has lectured on pharma marketing and spoken at events like Access USA 2026 on patient access challenges. His broad proficiency spans rare diseases, primary care, sales, marketing, market research, and global operations, earning him a reputation for effective planning across continents.
Lawrence.bressler@alumni.duke.edu
https://www.linkedin.com/in/lawrencebressler/
